Blog
RSS FeedPosted by Michael Wonder on 01 Jul 2023
New Zealand Pharmaceutical Schedule - 1 July 2023
1 July 2023 - The July 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 07 Jun 2023
PHARMAC confirms funding of rituximab for IgG4 related disease
7 June 2023 - PHARMAC has published a notification for widened access to rituximab (Riximyo) for people with the chronic inflammatory ...
Posted by Michael Wonder on 05 Jun 2023
New treatments for Australians with endometrial cancer and Lennox-Gastaut syndrome
5 June 2023 - From 1 June 2023, Australians with endometrial cancer and Lennox-Gastaut syndrome will have access to new ...
Posted by Michael Wonder on 01 Jun 2023
BMS Korea wins insurance coverage for myelofibrosis drug Inrebic
1 June 2023 - BMS Korea has announced that Inrebic (fedratinib), its myelofibrosis drug, will now be covered by the ...
Posted by Michael Wonder on 01 Jun 2023
Antengene announces Xpovio plus bortezomib and dexamethasone included for reimbursement by the PBS in Australia for the treatment of relapsed and/or refractory multiple myeloma
31 May 2023 - This inclusion by the PBS for the treatment of patients with relapsed and/or refractory multiple myeloma who ...
Posted by Michael Wonder on 31 May 2023
New Zealand Pharmaceutical Schedule - 1 June 2023
1 June 2023 - The June 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 May 2023
Schedule of Pharmaceutical Benefits - 1 June 2023
1 June 2023 - The June 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 01 May 2023
New Zealand Pharmaceutical Schedule - 1 May 2023
The May 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Apr 2023
Schedule of Pharmaceutical Benefits - 1 May 2023
1 May 2023 - The May 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 21 Apr 2023
Publication of stage 1 and stage 2 PBS process improvements metrics report (2021-22)
21 April 2023 - The 2021-22 Stage 1 and Stage 2 PBS process improvements metrics report is now available. ...
Posted by Michael Wonder on 06 Apr 2023
Life changing cystic fibrosis treatment now available to children 6 years and above
6 April 2023 - From 1 May 2023, children aged 6 to 11 with cystic fibrosis will have access to ...
Posted by Michael Wonder on 03 Apr 2023
Nucala (mepolizumab) is now listed on the PBS for Australians with chronic rhinosinusitis with nasal polyps
3 April 2023 - Nucala is the first biologic treatment to be PBS-subsidised for the treatment of severe chronic rhinosinusitis with ...
Posted by Michael Wonder on 01 Apr 2023
Schedule of Pharmaceutical Benefits - 1 April 2023
1 April 2023 - The April 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 02 Mar 2023
Affordable treatment for recurrent melanoma
2 March 2023 - From 1 March 2023, Australians with recurrent melanoma will have a new treatment option subsidised by the ...
Posted by Michael Wonder on 28 Feb 2023
Schedule of Pharmaceutical Benefits - 1 March 2023
1 March 2023 - The March 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...